Eargo — IPO Roadshow (September 2022)
35 slides from Eargo's IPO roadshow presentation, Sep 7, 2022
Slide 1: Eargo Company Overview
Hear life to the fullest Eargo Company Overview September 2022
Slide 2: About This Presentation
About This Presentation This presentation shall not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed rights offering transaction or (ii) an offer, nor a solicitation of an offer, of the sale or purchase of securities, nor
Slide 3: Additional Information
Additional Information The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for
Slide 4: Legal Disclaimers and Forward-Looking Statements (cont.)
| 4 Lin, F. R., Niparko, J. K., & Ferrucci, L. (2011). Hearing Loss Prevalence in the United States. Archives of Internal Medicine, 171(20), 1851– 1852; Prevalence of Hearing Loss by Severity in the United States, Adele M. Goman, PhD, and Frank R. Lin, MD, PhD, 2016; U.S. Census International Databa
Slide 5: Investment from Patient Square Capital, Rights Offering and Associated Proxy Proposals
Investment from Patient Square Capital, Rights Offering and Associated Proxy Proposals
Slide 6: Summary of Patient Square Capital Investment
6 Summary of Patient Square Capital Investment | 6 On June 24, 2022, the Company entered into a note purchase agreement (the “Note Purchase Agreement”) with Patient Square Capital (“PSC”) pursuant to which it agreed to (i) issue and sell up to $125 million in senior secured convertible notes (the “N
Slide 7: The Financing Is Intended to Finance Initiatives to Accelerate Omni-Channel Growth
| 7 1 2 3 4 Potentially regain insurance coverage under the FEHB program and other insurance programs Refine and expand physical retail strategy Optimize Cash-Pay business Invest in continued innovation The Financing Is Intended to Finance Initiatives Designed to Accelerate the Company’s Omni-Channe
Slide 8: Patient Square Capital Investment – Conversion
Patient Square Capital Investment – Conversion The Notes will be convertible into shares of our common stock (“Conversion Shares”), with the terms of such conversion to be determined by the timing of and level of participation by existing stockholders in the Rights Offering If the Company is able to
Slide 9: Rights Offering Key Facts
Rights Offering Key Facts The Rights Offering is a distribution of rights (the “Rights”) on a pro rata basis to the Company’s stockholders who hold shares as of a record date to be determined. Stockholders will receive one Right for every share of common stock. The Company does not intend for the re
Slide 10: Rights Offering Purpose and Rationale
Rights Offering Purpose and Rationale The Rights Offering provides existing stockholders the opportunity to reduce their dilution exposure as a result of the Financing Depending on participation in the Rights Offering, the aggregate net proceeds to the Company will range between $25 million to $37.5
Slide 11: Illustrative Existing Stockholder Subscription
Illustrative Existing Stockholder Subscription Net Cash to Eargo(1) Existing Stockholders PSC Shares Issued % Ownership Post-Offering Shares Issued % Ownership Post-Offering 0 Shares $25.0M(2) - 9.5% 375M 90.5% 75M Shares 37.5M(3) 75M 27.6% 300M 72.4% 375M Shares 37.5M(3) 375M 100% - 0% | 11 Notes:
Slide 12: Pro Forma Ownership: Rights Offering Completed by November 25, 2022
Pro Forma Ownership: Rights Offering Completed by November 25, 2022 | 12 As of July 1, 2022 Pro Forma for the Rights Offering (if completed by November 25, 2022)(1) 0 Stockholder Subscriptions 74,000,000 Stockholder Subscriptions 75,000,000 Stockholder Subscriptions 375,000
Slide 13: Pro Forma Ownership: Rights Offering Completed after November 25, 2022
Pro Forma Ownership: Rights Offering Completed after November 25, 2022 but before December 24, 2022 | 13 As of July 1, 2022 Pro Forma for the Rights Offering (if completed between November 25, 2022 and December 24, 2022)(1) 0 Stockholder Subscriptions 75,000,000 Stockholder Subscri
Slide 14: 2022 Annual Meeting Proxy Proposals
The Company has announced that it will be holding its 2022 Annual Meeting of Stockholders on October 12, 2022 (the “Annual Meeting”) In connection with the Annual Meeting, the Company is soliciting proxies from the stockholders with respect to the following two proposals required in connection with
Slide 15: Proxy Proposal #5: Share Increase Amendment
Proxy Proposal #5: Share Increase Amendment The issuance of shares of the Company’s common stock pursuant to the contemplated Rights Offering and the related conversion of the Notes under to the Note Purchase Agreement requires that the stockholders adopt an amendment to the Company’s Amended and Re
Slide 16: Proxy Proposal #6: Nasdaq Approval
Proxy Proposal #6: Nasdaq Approval The conversion of the Notes into, and the issuance of, the Conversion Shares upon completion of the contemplated Rights Offering requires the approval of our stockholders The Company is subject to Nasdaq Listing Rule 5635, which requires that, among other things, t
Slide 17: Proxy Proposal #4: Approval of Reverse Stock Split
Proxy Proposal #4: Approval of Reverse Stock Split The Board is recommending that stockholders adopt an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock, with a ratio in the range of 1-for-5 and 1-for-50, such
Slide 18: Rights Offering Timeline
RIGHTS OFFERING TIMELINE | 18
Slide 19: Business Priorities and Omni-Channel Strategy
Business Priorities and Omni-Channel Strategy
Slide 20: Leveraging Omni-channel to Scale the Business
Channel Eargo Status Cash Pay 22K FY21 shipments Shipments CAGR of 40%1 Post-DOJ settlement, adjusted media spend to dedicate efforts in cash pay channel Cash pay conversion rate nearly 16% in 2Q22(vs. 7% in 4Q21 and 11% in 1Q22) Repeat (Cash Pay) 3K FY21 shipments Shipments CAGR of 190%2 As a perce
Slide 21: Leveraging Omni-channel to Scale the Business (cont.)
Leveraging Omni-channel to Scale the Business (cont.) 21 Channel Eargo Status Insurance1 ~50% total shipments in 2021, prior to DOJ investigation 44% of total FY21 shipments, due to Q4 DOJ impact Shipments CAGR of 325%2 We estimate that more than 12 million adults over 50 in the U.S. have both heari
Slide 22: Company Background
Company Background
Slide 23: Untreated Hearing Loss Is a Big Problem
UNTREATED HEARING LOSS IS A BIG PROBLEM Greater risk of being diagnosed with dementia1 Risk doubles with mild hearing loss Risk triples with moderate hearing loss Hearing aids have been identified as one of the top potentially modifiable risk factors for dementia2 Greater risk of cognitive decline3
Slide 24: 45M U.S. Adults with Hearing Loss
>$8b 45M U.S. Adults with Hearing Loss1 Low Awareness Low Accessibility High Stigma High Cost Annual U.S. Hearing Aid Sales in 20192 Lin, F. R., Niparko, J. K., & Ferrucci, L. (2011). Hearing Loss Prevalence in the United States. Archives of Internal Medicine, 171(20), 1851– 1852; Prevalence of Hear
Slide 25: Significant Unmet Need
Significant Unmet Need Age 50+ with Mild or Moderate Hearing Loss and Above Median Household Income2,3 Adults in the U.S. with Hearing Loss Age 50+ with Mild or Moderate Hearing Loss2,3 Eargo U.S. Addressable Market Lin, F. R., Niparko, J. K., & Ferrucci, L. (2011). Hearing Loss Prevalence in the Un
Slide 26: Eargo customers are new to the category
Eargo customers are new to the category1 Represents Eargo customers who responded that they had never previously purchased a hearing aid device in a phone survey conducted upon receiving shipment of product from June 2019 to June 2022, of which approximately 80% of customers responded. WE BELIEVE WE
Slide 27: Eargo Addresses Limitations of Hearing Aids Sold in Traditional Channels
Traditional hearing aids Eargo Estimates of hearing aids sold through traditional channels in the United States. Cost data is on a per-pair basis. Eargo Addresses Limitations of Hearing Aids Sold in Traditional Channels | 27 Stigmatized, Visible, Unattractive Ear Canal Occlusion, Discomfort Battery
Slide 28: Revolutionary Products
High-quality audio comparable to BTE devices from major manufacturers1 Patented tip designs provide comfortable, non-occluding fit revolutionary TECHNOLOGY; Remote support *Only available on Neo HiFi Revolutionary Products Up to 16 hours of rechargeable battery life interact via phone, email, text o
Slide 29: High Cadence of Purposeful Innovation
| 29 Improving Performance, Fit and Comfort 2017 EARGO PLUS1 2018 EARGO MAX 2019 EARGO NEO1 2Q21 EARGO 5 2020 EARGO NEO HIFI 2022 EARGO 6 Improved durability Improved acoustic performance Refined cosmetics Connected charger Smartphone app Improved Flexi Palms Improved fidelity, feedback cancellation
Slide 30: Online Model Transforms Consumer Journey
PCP / ENT visit or referral Call Audiologist for appointment Hearing Exam at clinic Fitting Appt. Further Adjustment in-person needed Follow-up Visits as needed Traditional Path:Weeks to Months Discover and learn through Eargo website or physical presence Consult with a trained Eargo Sales Consultan
Slide 31: Sophisticated, Multi-Channel Customer Acquisition
| 31 Sophisticated, Multi-Channel Customer Acquisition Product Shipment Awareness / Demand Drivers Offline/print online PR Lead Collection Lead Conversion Customer Type TV Inbound Phone Direct Purchase (Web) Sales Consultants/ Hearing Professionals Online Hearing Screening Online Experience Segmente
Slide 32: Management Team with Proven Track Record of Execution
Management Team with Proven Track Record of Execution | 32 Christy La Pierre CLO General Counsel, Pebble IP & Patent Litigation Christian Gormsen CEO SVP Operations, Europe and Strategic Accounts, GN Group Group Commercial Director EMEA, ISS A/S Bill Brownie COO President & CEO, HearingPlanet Managi
Slide 33: Opportunities for Value Creation
| 33 Opportunities for Value Creation Capabilities to expand penetration into a significant addressable market across cash-pay and insurance channels1 Differentiated, high-quality product offering meeting large unmet need Pioneering DTC business model across demand generation, customer experience an
Slide 34: Appendix
Appendix
Slide 35: Rights Offering Participation Mechanics
Rights Offering Participation Mechanics The Rights Offering will be a distribution of Rights on a pro rata basis to the Company’s stockholders who hold shares as of a record date to be determined. Stockholders will receive one Right for every share of common stock, each Right granting the holder bas